1. [Treatment of patients with COVID-19 on Hemodialysis: Efficacy of Remdesivir].
- Author
-
Nakaya A, Kondo M, Ogura E, Katayama Y, Yoshino E, Hozumi K, Tago S, Teranishi Y, Minamibashi Y, Harada M, Kawano Y, Arai Y, Kobayashi M, Kouyama A, Yoshida K, Shimizu S, Ogura K, and Iwashita K
- Abstract
Background: There is no standard therapy for hemodialysis (HD) patients with COVID-19. Data on remdesivir in HD patients with COVID-19 are scarce., Methods: We retrospectively analyzed 25 HD patients with COVID-19 treated with remdesivir., Results: The median age of the patients was 78 years (range, 45-92 years) and was predominantly male (84%). A total of 44% of the patients had mild disease, 36% had moderate-1, and 20% had moderate-2. The most common symptoms were fever (76%) and coughing (44%). The most common comorbidity was renal failure (100%), followed by hypertension (60%) and cardiac disease (44%). The most frequent biomarker was elevated creatinine (100%), followed by C-reactive protein (80%), lymphopenia (76%), and D-dimer (68%). C-reactive protein levels decreased significantly before and after remdesivir administration (p < 0.001). Two patients showed deterioration, but none died. All patients recovered from COVID-19 and no adverse effects of treatment with remdesivir were observed., Conclusion: Our study suggests the safe use of remdesivir in HD patients with COVID-19., (© 2022 Sociedad Española de Nefrología. Published by Elsevier España, S.L.U.)
- Published
- 2022
- Full Text
- View/download PDF